Biomarker News and Research

RSS

A biomarker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition. Also called molecular marker and signature molecule.

NEDD9 protein stimulates aggressive metastatic breast cancer

Researchers at Fox Chase Cancer Center have demonstrated that a protein called NEDD9 may be required for some of the most aggressive forms of breast cancer to grow. Their findings, based on the study of a mouse model of breast cancer, are presented in a recent issue of Cancer Research, available on-line now.

3 Oct 2009

SNM's joint session with CMOD on molecular imaging biomarkers in clinical research

SNM is collaborating with the International Partnership for Critical Markers of Disease (CMOD) during CMOD's 7th Annual Biomarkers and Surrogate Endpoints Symposium, Bethesda North Marriott Hotel and Conference Center, Bethesda, Md., Oct. 19th, 2009.

3 Oct 2009

SFC Fluidics to develop handheld traumatic brain injury diagnostic device for the U.S. Army

SFC Fluidics, LLC recently announced it has received a contract for approximately $5 million from the Congressionally Directed Medical Research Program for development of a handheld device for rapid diagnosis of traumatic brain injury (TBI). More than 1.5 million Americans suffer head injuries each year, and TBI has become a signature injury for American troops serving in the wars in Iraq and Afghanistan.

30 Sep 2009

Metabolomics identifies biomarkers for periodontitis and gingivitis

...

30 Sep 2009

Response Genetics launches new genetic diagnostic test for gastric cancer

Response Genetics, Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, announced today the availability of its ResponseDX: Gastric™ genetic test panel, a proprietary PCR-based diagnostic test. By analyzing the expression of genes that correlate with response to commonly used chemotherapy agents, physicians can better tailor treatment for their patients with gastric cancer and gastroesophageal (GE) junction cancer.

29 Sep 2009

Lecture to focus on the increasing need to fund and develop methods of contraception

On October 2nd, 2009, Henry Gabelnick PhD, Executive Director of The CONRAD Program, will give the prestigious Alan F. Guttmacher lecture at the 2009 Association for Reproductive Health Professionals conference being held in Los Angeles, California.

29 Sep 2009

PROSPECT clinical trial results announced

Abbott today announced primary results from its groundbreaking PROSPECT (Providing Regional Observations to Study Predictors of Events in the Coronary Tree) clinical trial.

25 Sep 2009

Athera Biotechnologies and ALPCO sign distribution agreement

Athera Biotechnologies AB, an atherosclerosis R&D company developing novel products for treatment and prevention of cardiovascular disease (CVD), and ALPCO, a company providing high quality research immunoassays, announced today that they have signed a distribution agreement.

25 Sep 2009

PNNL Department of Energy researcher earns prestigious NIH Director's New Innovator Award

An analytical chemist at the Department of Energy's Pacific Northwest National Laboratory has been recognized with a National Institutes of Health Director's New Innovator Award. The award will support Wei-Jun Qian's drive to make new research and clinical diagnostic tools that are dramatically more sensitive, reliable and faster than current technologies.

24 Sep 2009

Hsp-27 protein: An indicator of prostate cancer progression

In the largest study of its kind, the international team of pathologists studied an initial 4,000 prostate cancer patients over a period of 15 years to further understanding into the natural progression of the disease and how it should be managed. The research, published in the British Journal of Cancer, could be used to develop a blood test to distinguish between aggressive and non-aggressive forms of prostate cancer.

24 Sep 2009

VisEn launches new imaging agent for monitoring key hypertension and renal disease biomarker

VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today the commercial launch of its new ReninSense680(TM) FAST imaging agent for measuring and monitoring a key hypertension and renal disease biomarker in vivo.

24 Sep 2009

New Fluorescence Molecular Tomography imaging systems from VisEn Medical

VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced the launch and availability of a new Fluorescence Molecular Tomography (FMT) imaging system -- the FMT 1500, and an advanced version of its FMT 2500, the FMT 2500 LX.

23 Sep 2009

Interleukin Genetics reports positive results from clinical study on weight management

Interleukin Genetics, Inc. (NYSE Amex: ILI) announced today top-line positive results from a retrospective clinical study on weight management using patients who participated in a diet study previously reported in the Journal of the American Medical Association.

23 Sep 2009

Amgen announces Phase 3 results evaluating Vectibix in combination with FOLFIRI chemotherapy

Amgen (Nasdaq: AMGN) today announced detailed results from the Phase 3 '181' trial evaluating Vectibix((R)) (panitumumab) in combination with FOLFIRI (an irinotecan based chemotherapy), as a second-line treatment for metastatic colorectal cancer (mCRC). In this trial, Vectibix significantly improved progression-free survival (PFS) in patients with KRAS wild-type mCRC.

22 Sep 2009

Bayer's regorafenib showed 50% stabilization rate in RCC patients

Bayer today announced results from a Phase II trial of regorafenib (BAY 73-4506), a potent oral multi-kinase inhibitor, which demonstrated that treatment with regorafenib resulted in a 31 percent partial response rate and 50 percent stabilization rate in patients with metastatic renal cell carcinoma (RCC).

22 Sep 2009

Vitae Pharmaceuticals initiates Phase 1 clinical trial of its novel cardiovascular agent

Vitae Pharmaceuticals, Inc., an integrated discovery and development company, today announced that it has initiated a Phase 1 clinical trial of its novel cardiovascular agent, VTP-27999.

21 Sep 2009

NIAID awards Antigen Discovery a Phase II STTR grant for Chlamydia vaccine development

Antigen Discovery, Inc. ("ADi", formerly ImmPORT Therapeutics, Inc.), a leading biotech company in high throughput antigen and biomarker discovery, announced today that the Company was awarded a Phase II STTR from the National Institute of Allergy and Infectious Diseases (NIAID) under the American Recovery and Reinvestment Act (ARRA) of 2009.

21 Sep 2009

Researchers receive grants to study Alzheimer's disease

Five early-career scientists were awarded The Rosalinde and Arthur Gilbert Foundation/AFAR New Investigator Awards in Alzheimer's Disease. The $75,000 awards provide a broad array of funding in the biological, genetic, and environmental causes of AD.

21 Sep 2009

Health Discovery Corporation appoints new COO

Health Discovery Corporation, a personalized medicine company specializing in molecular diagnostics including gene-based testing, as well as computer assisted diagnostics in digital pathology and radiology, announced that former Deputy FDA Commissioner John A. Norris has been appointed as Chief Operating Officer (COO) of the Company.

19 Sep 2009

Research program to study personalized medicine

A new collaborative research program that will use the power of metabolomic profiling to help advance the concept of personalized medicine was announced September 17, 2009 by the Burnham Institute for Medical Research and the Sarah W. Stedman Nutrition and Metabolism Center at Duke University Medical Center.

18 Sep 2009

Biomarker News and Research

Further Reading

NEDD9 protein stimulates aggressive metastatic breast cancer

SNM's joint session with CMOD on molecular imaging biomarkers in clinical research

SFC Fluidics to develop handheld traumatic brain injury diagnostic device for the U.S. Army

Metabolomics identifies biomarkers for periodontitis and gingivitis

Response Genetics launches new genetic diagnostic test for gastric cancer

Lecture to focus on the increasing need to fund and develop methods of contraception

PROSPECT clinical trial results announced

Athera Biotechnologies and ALPCO sign distribution agreement

PNNL Department of Energy researcher earns prestigious NIH Director's New Innovator Award

Hsp-27 protein: An indicator of prostate cancer progression

VisEn launches new imaging agent for monitoring key hypertension and renal disease biomarker

New Fluorescence Molecular Tomography imaging systems from VisEn Medical

Interleukin Genetics reports positive results from clinical study on weight management

Amgen announces Phase 3 results evaluating Vectibix in combination with FOLFIRI chemotherapy

Bayer's regorafenib showed 50% stabilization rate in RCC patients

Vitae Pharmaceuticals initiates Phase 1 clinical trial of its novel cardiovascular agent

NIAID awards Antigen Discovery a Phase II STTR grant for Chlamydia vaccine development

Researchers receive grants to study Alzheimer's disease

Health Discovery Corporation appoints new COO

Research program to study personalized medicine

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest Life Science News